RxDoctor Payments Data

Megan Duncan, PA

Medical · Athens, GANPI 1821442138

Payments from drug & device makers

$9,661in general payments, 2019–2025

Across 468 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$899
  • Novartis$591
  • AstraZeneca$501
  • GSK$495
  • Johnson & Johnson$462
  • Pfizer$422
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,09594%
  • Education$5666%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck42$899
Novartis26$591
AstraZeneca(2 entities)16$501
GSK34$495
Johnson & Johnson(2 entities)21$462
Pfizer23$422
Stemline Therapeutics Inc.17$415
Daiichi Sankyo Inc.21$412
AbbVie16$355
Gilead(2 entities)12$347
Takeda Pharmaceuticals U.S.A., Inc.13$308
Seagen Inc.14$288
Genentech USA, Inc.12$235
Sanofi8$197
Karyopharm Therapeutics Inc.9$189
Eisai Inc.9$173
Bristol Myers Squibb9$171
Lilly USA, LLC6$163
EMD Serono, Inc.8$135
Incyte Corporation7$134
Amgen7$129
Bayer6$127
Blueprint Medicines Corporation7$127
Jazz Pharmaceuticals Inc.7$126
Regeneron Healthcare Solutions, Inc.5$121
Rigel Pharmaceuticals, Inc.6$118
Exelixis Inc.6$114
AVEO Pharmaceuticals, Inc.6$110
Sobi, Inc5$103
ADC Therapeutics America, Inc.4$94
Array Biopharma Inc8$88
Astellas Pharma US Inc4$81
Pharmacyclics LLC, An Abbvie Company3$79
Deciphera Pharmaceuticals Inc.4$73
Genmab U.S., Inc.4$70
Sanofi-aventis U.S. LLC1$68
Boehringer Ingelheim3$68
Amarin Pharma, Inc.4$63
E.r. Squibb & Sons, L.L.C.4$58
Acrotech Biopharma Inc.3$52
Puma Biotechnology, Inc.3$47
Dendreon Pharmaceuticals LLC2$45
Beigene USA, Inc.2$43
Syndax Pharmaceuticals, Inc.2$39
Cumberland Pharmaceuticals, Inc.2$39
Adaptive Biotechnologies Corporation3$39
Geron Corporation2$38
Spectrum Pharmaceuticals Inc.2$37
Sumitomo Pharma America, Inc.2$37
Sun Pharmaceutical Industries Inc.2$35
Kyowa Kirin, Inc.2$34
Epizyme, Inc.2$34
Telix Pharmaceuticals2$34
Coherus Oncology, Inc.1$30
Mirati Therapeutics, Inc.1$29
Beone Medicines USA, Inc.2$29
Delcath Systems1$26
Janssen Scientific Affairs, LLC1$26
Accord Healthcare, Inc.1$25
Tersera Therapeutics LLC1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,661 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$129,080
Medicare patients
34
Services billed
4,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KisqaliRibociclib Succinate38$463,688
XtandiEnzalutamide25$427,236
PomalystPomalidomide17$377,384
ImbruvicaIbrutinib16$250,317
PromactaEltrombopag Olamine13$249,991
IbrancePalbociclib16$249,236
JakafiRuxolitinib Phosphate11$193,062
VenclextaVenetoclax13$137,460
PegasysPeginterferon Alfa-2a13$58,197
EliquisApixaban68$44,029
Abiraterone Acetate17$32,676
XareltoRivaroxaban20$27,576
CreonLipase/Protease/Amylase14$12,545
Everolimus13$7,443
Imatinib Mesylate18$1,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisKisqali, Promacta$591$713,68051 claims
Astellas Pharma US IncXtandi$81$427,23625 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$58$377,38417 claims
PfizerIbrance, Eliquis$422$293,26584 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$79$250,31716 claims
Incyte CorporationJakafi$134$193,06211 claims
AbbVieVenclexta, Creon$355$150,00527 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$26$32,67617 claims
Johnson & JohnsonXarelto$462$27,57620 claims
Lilly USA, LLCOlanzapine$163$18413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.

Other medical in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →